The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: An update

Internal and Emergency Medicine

Volumn 7, Issue 4, 2012, Pages 299-304

  Rubboli, Andrea ^a  

^a MAGGIORE HOSPITAL   (Italy)

Author keywords

Antiplatelet agents; Oral anticoagulation; Percutaneous coronary intervention; Stent; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; TICLOPIDINE; WARFARIN;

DRUG COMBINATION; DRUG ELUTING STENT; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; RISK; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADMINISTRATION, ORAL; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK; TICLOPIDINE; WARFARIN;

EID: 84864400859     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0555-1     Document Type: Review

References (26)

1. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F, European Society of Cardiology Working Group on Thrombosis (2010) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 103: 13-28.
2. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY (2008) Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 40: 428-436.
3. Dewilde W, Ten Berg J (2009) Design and rationale of the WOEST trial: what is the optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 158: 713-718.
4. Vedovati MC, Becattini C, Agnelli G (2010) Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med 5: 281-290.
5. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146: 857-867.
6. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903-1912.
7. Rubboli A, Milandri M, Castelvetri C, Cosmi B (2005) Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 104: 101-106.
8. Rubboli A, Di Pasquale G (2007) Triple therapy of warfarin, aspirin and a thienopyridine for patients treated with vitamin K antagonists undergoing coronary stenting. A review of the evidence. Intern Emerg Med 2: 177-181.
9. Valencia J, Mainar V, Bordes P, Pineda J, Gómez S, Sogorb F (2008) Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment. J Interv Cardiol 21: 218-224.
10. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, Sirbu V, Bass TA, Della Rovere F, Gavazzi A, Angiolillo DJ (2008) Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 102: 1618-1623.
11. Ruiz-Nodar JM, Marín F, Sánchez-Payá J, Hurtado JA, Valencia-Martín J, Manzano-Fernández S, Roldán V, Pérez-Andreu V, Sogorb F, Valdés M, Lip GY (2009) Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 30: 932-939.
12. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, Finet G, Le Breton H, Boschat J, STENTICO Investigators (2009) Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 104: 338-342.
13. Hälg C, Brunner-La Rocca HP, Kaiser C, Jeger R, Osswald S, Pfisterer M, Hoffmann A, BASKET Investigators (2009) Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. EuroIntervention5: 425-431.
14. Karjalainen PP, Vikman S, Niemelä M, Porela P, Ylitalo A, Vaittinen MA, Puurunen M, Airaksinen TJ, Nyman K, Vahlberg T, Airaksinen KE (2008) Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 29: 1001-1010.
15. Lahtela H, Karjalainen PP, Niemelä M, Vikman S, Kervinen K, Ylitalo A, Puurunen M, Porela P, Nyman K, Hinkka-Yli-Salomäki S, Airaksinen KE (2009) Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? Thromb Haemost 102: 1227-1233.
16. Rubboli A, Colletta M, Valencia J, Capecchi A, Franco N, Zanolla L, La Vecchia L, Piovaccari G, Di Pasquale G, WARfarin and Coronary STENTing (WAR-STENT) Study Group (2009) Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 22: 390-397.
17. Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, Yan ZX, Yang SW, de Jia A, Yu M (2010) Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 74: 701-708.
18. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Task Force on Practice Guidelines, American College of Cardiology/American Heart Association, Committee for Practice Guidelines, European Society of Cardiology, European Heart Rhythm Association, Heart Rhythm Society (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J 27: 1979-2030.
19. Sambola A, Ferreira-González I, Angel J, Alfonso F, Maristany J, Rodríguez O, Bueno H, López-Minguez JR, Zueco J, Fernández-Avilés F, Román AS, Prendergast B, Mainar V, García-Dorado D, Tornos P (2009) Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 95: 1483-1488.
20. Fauchier L, Lip GY (2010) Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding. Europace 12: 761-763.
21. Roy P, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R (2008) Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 102: 1614-1617.
22. Lemesle G, Delhaye C, Bonello L, de Labriolle A, Waksman R, Pichard A (2008) Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Arch Cardiovasc Dis 101: 769-777.
23. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, DE Casey Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2009) 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 120: 2271-2306.
24. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
25. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody R, Gibson CM, Antman EM, for the TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
26. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, for the PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.